Loading
Prostate Cancer Diagnosis and Treatment / Ferroptosis and Cancer Prognosis · Journal article
Frontiers in Cellular and Infection Microbiology · September 8, 2026
Raises a question worth testing. It does not answer one.
This is a narrative review synthesizing observational and mechanistic evidence linking gut microbiota composition to prostate cancer risk, progression, and treatment response. The authors acknowledge that causal relationships remain unclear and that existing evidence derives largely from small, cross-sectional studies; they call for multicenter longitudinal cohorts and multi-omics studies to establish translational value.
Journal article. Prostate cancer patients; men at risk of prostate cancer.
PCa patients exhibit reduced fecal microbiota diversity and altered microbiota composition, with certain bacterial genera correlated with disease risk and progression Gut microbiota may regulate signaling pathways (IGF-1, MAPK/PI3K, NF-κB) through metabolites including short-chain fatty acids, bile acids, and microbiota-derived androgens Androgen deprivation therapy reshapes gut microbiota; certain bacterial populations may contribute to castration resistance through androgen metabolism
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Clinicians should recognize that gut microbiota alterations are associated with prostate cancer but understand that causal relationships, clinical utility for screening or prognosis, and efficacy of microbiota-targeted interventions remain unproven. Current evidence does not support routine microbiome assessment or intervention in prostate cancer practice.
This is a narrative review synthesizing observational associations and mechanistic hypotheses about the gut–prostate axis without reporting original trial data, causal evidence, or effect sizes.
Clinicians should recognize that gut microbiota alterations are associated with prostate cancer but understand that causal relationships, clinical utility for screening or prognosis, and efficacy of microbiota-targeted interventions remain unproven. Current evidence does not support routine microbiome assessment or intervention in prostate cancer practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Prostate cancer (PCa) is one of the most common malignant tumors in men, and its onset and progression may be closely associated with an imbalance in the gut microbiota. Existing studies indicate that PCa patients exhibit reduced fecal microbiota diversity and altered microbiota composition, with the abundance of certain bacterial genera correlated with disease risk and progression. Mechanistically, the gut microbiota may regulate signaling pathways such as IGF-1, MAPK/PI3K, and NF-κB through metabolites including short-chain fatty acids, bile acids, and microbiota-derived androgens, thereby potentially contributing to tumor proliferation, inflammatory responses, and immune evasion. Androgen deprivation therapy (ADT) can also reshape the gut microbiota; certain bacterial populations may contribute to the development of castration resistance through androgen metabolism, while changes in bacteria such as Akkermansia muciniphila are associated with treatment response. Currently, strategies such as dietary interventions, probiotics, and fecal microbiota transplantation have shown some promise; however, most existing studies are small-sample or cross-sectional in nature, and causal relationships remain unclear. Future studies should combine multicenter longitudinal cohorts with multi-omics technologies to further elucidate the translational value of the gut microbiota in PCa screening, risk stratification, prognostic assessment, treatment-response prediction, toxicity monitoring, and personalized microbiome-targeted interventions.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.